{
    "id": 1,
    "premise": "none",
    "hypothesis": "There are two potential treatment options for this patient.",
    "label": "entailment",
    "explanation": "Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nRucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "There are two potential treatment options for this patient.",
        "refined explanation": "Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality.\nRucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
        "refined iteration": 1,
        "history explanation": [
            "0 iteration: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nRucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
            "1 iteration: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality.\nRucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality.\nPatients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Therefore, there exist two treatment options for the patient z. *)\\nthen show ?thesis sledgehammer', 'solving time': 134.14449381828308, 'proof tactics': [], 'code': 'theory clinical_1_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  UseFor :: \"entity \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  PatientEvent :: \"event \u21d2 entity \u21d2 bool\"  (* Renamed to avoid conflict *)\\n  Cause :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  Cell :: \"entity \u21d2 entity\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  DNA :: \"entity \u21d2 entity\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  For :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Olaparib is a PARP1 inhibitor licenced for use in prostate cancer patients. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y. Olaparib x \u2227 PARP1Inhibitor x \u2227 ProstateCancerPatient y \u27f6 UseFor x y\"\\n\\n(* Explanation 2: Rucaparib is a PARP1 inhibitor licenced for use in prostate cancer patients. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y. Rucaparib x \u2227 PARP1Inhibitor x \u2227 ProstateCancerPatient y \u27f6 UseFor x y\"\\n\\n(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e1 e2 e3 w v. Patient x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 PatientEvent e1 y \u2227 Cause e2 \u2227 Agent e2 z \u2227 Rely e3 \u2227 Agent e3 (Cell x) \u2227 Mechanism w \u2227 Singular w \u2227 Repair e3 \u2227 Damage v \u2227 Cumulative v \u2227 To v (DNA x)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient z\"\\n  (* Hypothesis: There are two potential treatment options for this patient. *)\\n  shows \"\u2203x y. TreatmentOption x \u2227 TreatmentOption y \u2227 Patient z \u2227 For x z \u2227 For y z\"\\nproof -\\n  (* From the premise, we have the known information about the patient. *)\\n  from asm have \"Patient z\" <ATP>\\n  (* Explanation 1 and Explanation 2 provide information about Olaparib and Rucaparib being used for prostate cancer patients. *)\\n  (* We can consider Olaparib and Rucaparib as potential treatment options. *)\\n  (* Since both are licensed for use in prostate cancer patients, they can be considered treatment options for the patient z. *)\\n  have \"TreatmentOption Olaparib \u2227 TreatmentOption Rucaparib\" <ATP>\\n  (* Since Olaparib and Rucaparib are treatment options, and they are used for prostate cancer patients, we can infer they are for patient z. *)\\n  then have \"For Olaparib z \u2227 For Rucaparib z\" <ATP>\\n  (* Therefore, there exist two treatment options for the patient z. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients (from Explanatory Sentence 1)\\nB: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients (from Explanatory Sentence 2)\\nC: Patients with loss of BRCA2 may benefit from PARP1 inhibition (from Explanatory Sentence 3)\\nD: Synthetic lethality causes cells to rely on a singular mechanism to repair cumulative damage to DNA (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(C, D)\\nImplies(Patients with loss of BRCA2 may benefit from PARP1 inhibition, Synthetic lethality causes cells to rely on a singular mechanism to repair cumulative damage to DNA)\\n--------\\n\\nDerived Implications:\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 7.624561786651611, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'vampire found a proof...', 'e found a proof...', 'zipperposition found a proof...', 'zipperposition: Try this: by (simp add: explanation_1) (2 ms)', 'e: Try this: by (simp add: explanation_2) (3 ms)', 'cvc4: Try this: using explanation_2 by presburger (4 ms)', 'zipperposition: Found duplicate proof', 'vampire: Try this: using explanation_1 by presburger (4 ms)', 'Done'], 'code': 'theory clinical_1_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Olaparib :: \"entity \u21d2 bool\"\\n  Rucaparib :: \"entity \u21d2 bool\"\\n  PARP1Inhibitor :: \"entity \u21d2 bool\"\\n  LicensedForUseIn :: \"entity \u21d2 entity \u21d2 bool\"\\n  ProstateCancerPatient :: \"entity \u21d2 bool\"\\n  TreatmentOption :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  DueTo :: \"entity \u21d2 entity \u21d2 bool\"\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Cell :: \"entity\"\\n  SingularMechanism :: \"entity\"\\n  CumulativeDamage :: \"entity\"\\n  DNA :: \"entity\"\\n\\n(* Explanation 1: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z w. Olaparib x \u2227 PARP1Inhibitor x \u2227 LicensedForUseIn x y \u2227 ProstateCancerPatient y \u2227 TreatmentOption x \u2227 Patient z \u2227 LossOfBRCA2 z \u2227 DueTo z w \u2227 SyntheticLethality w\"\\n\\n(* Explanation 2: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients and is a treatment option for patients with loss of BRCA2 due to synthetic lethality. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z w. Rucaparib x \u2227 PARP1Inhibitor x \u2227 LicensedForUseIn x y \u2227 ProstateCancerPatient y \u2227 TreatmentOption x \u2227 Patient z \u2227 LossOfBRCA2 z \u2227 DueTo z w \u2227 SyntheticLethality w\"\\n\\n(* Explanation 3: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e1 e2 e3 e4. Patient x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Source e1 y \u2227 SyntheticLethality z \u2227 Cause e2 \u2227 Agent e2 z \u2227 Rely e3 \u2227 Agent e3 Cell \u2227 On e3 SingularMechanism \u2227 Repair e4 \u2227 Agent e4 SingularMechanism \u2227 To e4 DNA\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient y\"\\n  (* Hypothesis: There are two potential treatment options for this patient. *)\\n  shows \"\u2203x y. TreatmentOption x \u2227 Patient y \u2227 LicensedForUseIn x y\"\\nproof -\\n  (* From the premise, we have the known information about the patient. *)\\n  from asm have \"Patient y\" <ATP>\\n  (* Explanation 1 and Explanation 2 provide information about Olaparib and Rucaparib being treatment options. *)\\n  (* We have logical relations Implies(A, B) and Implies(C, D) from Explanatory Sentences 1 and 2. *)\\n  (* These imply that both Olaparib and Rucaparib are treatment options for patients with loss of BRCA2 due to synthetic lethality. *)\\n  (* Since both Olaparib and Rucaparib are licensed for use in prostate cancer patients, they are treatment options. *)\\n  have \"TreatmentOption Olaparib \u2227 LicensedForUseIn Olaparib y\" <ATP>\\n  moreover have \"TreatmentOption Rucaparib \u2227 LicensedForUseIn Rucaparib y\" <ATP>\\n  ultimately show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients (from Explanatory Sentence 1)\\nB: Olaparib is a treatment option for patients with loss of BRCA2 due to synthetic lethality (from Explanatory Sentence 1)\\nC: Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients (from Explanatory Sentence 2)\\nD: Rucaparib is a treatment option for patients with loss of BRCA2 due to synthetic lethality (from Explanatory Sentence 2)\\nE: Patients with loss of BRCA2 may benefit from PARP1 inhibition (from Explanatory Sentence 3)\\nF: Synthetic lethality causes cells to rely on a singular mechanism to repair cumulative damage to DNA (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(Olaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, Olaparib is a treatment option for patients with loss of BRCA2 due to synthetic lethality)\\n--------\\nImplies(C, D)\\nImplies(Rucaparib is a PARP1 inhibitor licensed for use in prostate cancer patients, Rucaparib is a treatment option for patients with loss of BRCA2 due to synthetic lethality)\\n--------\\nImplies(E, F)\\nImplies(Patients with loss of BRCA2 may benefit from PARP1 inhibition, Synthetic lethality causes cells to rely on a singular mechanism to repair cumulative damage to DNA)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}